Skip to main content

Alnylam Says Key Tuschl-II Claims Upheld by Japanese Patent Office

Premium

Alnylam Pharmaceuticals this week announced that the Japanese Patent Office has upheld certain key claims within the company's Tuschl-II patent during invalidation proceedings initiated at the request of Bio Think-Tank, a Japanese company.

Tuschl-II is a family of patents and patent applications broadly related to siRNAs, between 21 to 23 nucleotides long, and with 2- to 3-nucleotide-long 3' overhangs, that can target specific mRNA degradation in mammals. It is named for Rockefeller University researcher and Alnylam co-founder Thomas Tuschl, and is exclusively licensed to Alnylam.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.